$ANIK
Anika Therapeutics, Inc. Stock $anik

$anik Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000115752313003914 Filed on August 06, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2013 Q1
Revenue	$17.75M	$20.83M	$15.25M
YoY Change	20.2%	6.13%	6.17%
Cost Of Revenue	$5.380M	$6.311M	$4.841M
YoY Change	-25.5%	-21.93%	-24.52%
Gross Profit	$12.38M	$14.52M	$10.41M
YoY Change	81.14%	34.44%	44.53%
Gross Profit Margin	69.75%	69.7%	68.25%
Selling, General & Admin	$3.190M	$3.401M	$3.947M
YoY Change	-11.43%	-17.23%	17.79%
% of Gross Profit	25.77%	23.43%	37.93%
Research & Development	$1.620M	$1.829M	$1.583M
YoY Change	33.1%	40.89%	3.25%
% of Gross Profit	13.09%	12.6%	15.21%
Depreciation & Amortization	$1.310M	$1.070M	$1.202M
YoY Change	11.02%	-10.08%	21.81%
% of Gross Profit	10.58%	7.37%	11.55%
Operating Expenses	$4.810M	$5.230M	$5.530M
YoY Change	-0.18%	-3.27%	13.22%
Operating Profit	$7.570M	$9.398M	$5.011M
YoY Change	177.62%	53.22%	63.61%
Interest Expense	-$30.00K	-$36.38K	-$39.56K
YoY Change	-33.57%	-25.95%	-22.74%
% of Operating Profit	-0.4%	-0.39%	-0.79%
Other Income/Expense, Net
YoY Change
Pretax Income	$7.730M	$9.362M	$4.972M
YoY Change	188.26%	53.86%	65.08%
Income Tax	$2.780M	$3.467M	$1.904M
% Of Pretax Income	35.96%	37.03%	38.29%
Net Earnings	$4.960M	$5.895M	$3.068M
YoY Change	201.47%	57.75%	60.45%
Net Earnings / Revenue	27.94%	28.3%	20.12%
Basic Earnings Per Share		$0.44	$0.23
Diluted Earnings Per Share	$331.6K	$0.40	$0.21
COMMON SHARES
Basic Shares Outstanding	13.66M shares	13.51M shares	13.41M shares
Diluted Shares Outstanding		14.58M shares	14.36M shares

Balance Sheet

Concept	2013 Q3	2013 Q2	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$64.10M	$54.10M	$51.00M
YoY Change	60.65%	42.74%	50.0%
Cash & Equivalents	$64.10M	$54.14M	$50.97M
Short-Term Investments
Other Short-Term Assets	$2.900M	$2.900M	$3.000M
YoY Change	-12.12%	-9.38%	-21.05%
Inventory	$11.60M	$10.36M	$9.948M
Prepaid Expenses
Receivables	$16.50M	$19.07M	$14.78M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$95.00M	$86.47M	$78.69M
YoY Change	38.88%	24.25%	22.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$33.30M	$33.85M	$34.48M
YoY Change	-7.34%	-7.07%	-6.05%
Goodwill		$8.923M	$8.792M
YoY Change		3.43%	-3.91%
Intangibles		$19.00M	$19.23M
YoY Change		-11.67%
Long-Term Investments
YoY Change
Other Assets	$100.0K	$200.0K	$200.0K
YoY Change	-50.0%	0.0%	0.0%
Total Long-Term Assets	$61.90M	$61.92M	$62.66M
YoY Change	-6.88%	-7.27%	-9.45%
TOTAL ASSETS
Total Short-Term Assets	$95.00M	$86.47M	$78.69M
Total Long-Term Assets	$61.90M	$61.92M	$62.66M
Total Assets	$156.9M	$148.4M	$141.4M
YoY Change	16.33%	8.81%	6.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.100M	$2.700M	$2.697M
YoY Change	10.09%	-31.51%	-30.86%
Accrued Expenses	$5.200M	$4.504M	$4.253M
YoY Change	18.48%	5.33%	-1.1%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.600M	$1.600M	$1.600M
YoY Change	0.0%	0.0%	0.0%
Total Short-Term Liabilities	$10.40M	$11.70M	$10.74M
YoY Change	-14.44%	-23.09%	-16.74%
LONG-TERM LIABILITIES
Long-Term Debt	$6.800M	$7.200M	$7.600M
YoY Change	-19.05%	-18.18%	-17.39%
Other Long-Term Liabilities	$3.200M	$1.264M	$1.294M
YoY Change	107.9%	-17.63%	-78.07%
Total Long-Term Liabilities	$10.00M	$8.464M	$8.894M
YoY Change	0.61%	-18.1%	-41.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.40M	$11.70M	$10.74M
Total Long-Term Liabilities	$10.00M	$8.464M	$8.894M
Total Liabilities	$28.70M	$20.17M	$19.63M
YoY Change	29.9%	-21.07%	-43.9%
SHAREHOLDERS EQUITY
Retained Earnings		$54.97M	$49.08M
YoY Change		37.77%
Common Stock		$140.2K	$140.1K
YoY Change		1.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$128.2M	$119.4M	$112.8M
YoY Change
Total Liabilities & Shareholders Equity	$156.9M	$148.4M	$141.4M
YoY Change	16.33%	8.81%	6.12%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2013 Q1
OPERATING ACTIVITIES
Net Income	$4.960M	$5.895M	$3.068M
YoY Change	201.47%	57.75%	60.45%
Depreciation, Depletion And Amortization	$1.310M	$1.070M	$1.202M
YoY Change	11.02%	-10.08%	21.81%
Cash From Operating Activities	$7.530M	$3.560M	$6.069M
YoY Change	240.72%	-31.8%	-459.18%
INVESTING ACTIVITIES
Capital Expenditures	-$130.0K	-$70.00K	$35.80K
YoY Change	-7.14%	-92.47%	-84.02%
Acquisitions
YoY Change
Other Investing Activities	$280.0K	$110.0K	$140.0K
YoY Change
Cash From Investing Activities	$160.0K	$40.00K	$99.81K
YoY Change	-214.29%	-104.3%	-144.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net			$400.0K
YoY Change			0.0%
Cash From Financing Activities	2.160M	-420.0K	761.7K
YoY Change	-1450.0%	16.67%	600.49%
NET CHANGE
Cash From Operating Activities	7.530M	3.560M	6.069M
Cash From Investing Activities	160.0K	40.00K	99.81K
Cash From Financing Activities	2.160M	-420.0K	761.7K
Net Change In Cash	9.850M	3.180M	6.930M
YoY Change	415.71%	-19.08%	-483.96%
FREE CASH FLOW
Cash From Operating Activities	$7.530M	$3.560M	$6.069M
Capital Expenditures	-$130.0K	-$70.00K	$35.80K
Free Cash Flow	$7.660M	$3.630M	$6.033M
YoY Change	225.96%	-40.98%	-415.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2009Q4	us-gaap	Area Of Land AreaOfLand	26000	sqft
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13662136	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3800000	shares
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37909608
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1250000	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14017280	shares
CY2013Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2069444
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1600000
CY2013Q1	us-gaap	Goodwill Goodwill	8792165
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14017280	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2013Q2	us-gaap	Debt Instrument Interest Rate At Period End DebtInstrumentInterestRateAtPeriodEnd	0.0148	pure
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11701318
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-3063985
CY2013Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7200000
CY2013Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2162634
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17772147
CY2013Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1520096
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	67385076
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2699678
CY2013Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	469991
CY2013Q2	us-gaap	Restructuring Reserve RestructuringReserve	283063
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1264427
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	119433839
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	54972575
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1527917
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q2	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	283063
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4503551
CY2013Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	332148
CY2013Q2	us-gaap	Long Term Debt LongTermDebt	8800000
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	140173
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	148394650
CY2013Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	6725622
CY2013Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1370172
CY2013Q2	us-gaap	Goodwill Goodwill	8923197
CY2013Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18996886
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19065386
CY2013Q2	us-gaap	Inventory Net InventoryNet	10357798
CY2013Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	51618726
CY2013Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	1989422
CY2013Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2180056
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33846579
CY2013Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	2016882
CY2013Q2	us-gaap	Assets Assets	148394650
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54140459
CY2013Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	6160860
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3000000
CY2013Q2	anik	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	154050
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35777222
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13866060	shares
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	920873
CY2013Q2	us-gaap	Assets Current AssetsCurrent	86473938
CY2013Q2	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber	1900000	shares
CY2013Q2	anik	Intangible Assets Gross Carrying Amount IntangibleAssetsGrossCarryingAmount	28902686
CY2013Q2	anik	Intangible Assets Accumulated Amortization IntangibleAssetsAccumulatedAmortization	7204096
CY2013Q2	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingWeightedAverageRemainingContractualTerm	P6Y3M7D
CY2013Q2	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingIntrinsicValue	16200000
CY2013Q2	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice	8.60
CY2013Q2	anik	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	67767
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1250000	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13866060	shares
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2152778
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1600000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14452618
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-2654630
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8000000
CY2012Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2477833
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17263032
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1680212
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	65431424
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2341838
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	642853
CY2012Q4	us-gaap	Restructuring Reserve RestructuringReserve	933732
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1541124
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	108925134
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	46009681
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2875067
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	933732
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5837044
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	337459
CY2012Q4	us-gaap	Long Term Debt LongTermDebt	9600000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	138659
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	142069051
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	6997397
CY2012Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1798669
CY2012Q4	us-gaap	Goodwill Goodwill	9065891
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20334636
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21462481
CY2012Q4	us-gaap	Inventory Net InventoryNet	8283472
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	52376013
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	2031583
CY2012Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1396609
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35112981
CY2012Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	777056
CY2012Q4	us-gaap	Assets Assets	142069051
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44067477
CY2012Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6109807
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1539477
CY2012Q4	us-gaap	Assets Current AssetsCurrent	77384490
CY2012Q4	anik	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	102414
CY2012Q4	anik	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	171053
	dei	Trading Symbol TradingSymbol	ANIK
	dei	Entity Registrant Name EntityRegistrantName	ANIKA THERAPEUTICS INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0000898437
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.67
	us-gaap	Nature Of Operations NatureOfOperations	<div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 1.             Nature of Business</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> </div> </div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Anika Therapeutics, Inc. (together with its subsidiaries, “Anika,” the “Company,” “we,” “us,” or “our”) develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. These products are based on hyaluronic acid (“HA”), a naturally occurring, biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number of physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is subject to risks common to companies in the biotechnology and medical device industries including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with the U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements as well as the ability to grow the Company’s business.</font></div> </div>
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.62
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14484978	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5760	pure
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1025929	shares
	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	500000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0070	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.375	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13459049	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0061	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	374500	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	9632926
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	459969	shares
	us-gaap	Restructuring Reserve Period Increase Decrease RestructuringReservePeriodIncreaseDecrease
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	246785
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1430484
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1270885
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-440210
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	878228
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-271532
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1127875
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2270895
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	7596
	us-gaap	Payments For Restructuring PaymentsForRestructuring	659110
	us-gaap	Sales Revenue Net SalesRevenueNet	36075388
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	109871
	us-gaap	Restructuring Reserve Translation Adjustment RestructuringReserveTranslationAdjustment	8441
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-16998
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	14333977
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	34561896
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	800000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-75939
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	1513492
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-409355
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1796522
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-703303
	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	8553539
	us-gaap	Operating Income Loss OperatingIncomeLoss	14409916
	us-gaap	Net Income Loss NetIncomeLoss	8962894
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2324269
	us-gaap	Inventory Write Down InventoryWriteDown	229885
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	11152502
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-269149
	us-gaap	Costs And Expenses CostsAndExpenses	21665472
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	335471
	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	7596
	us-gaap	Share Based Compensation ShareBasedCompensation	788326
	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	-142694
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	10072982
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1127875
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7347793
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5371083
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-32329
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1034408
	us-gaap	Restructuring Charges RestructuringCharges	246785
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	788326
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	136914
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3411962
	anik	Intangible Assets Translation Adjustments IntangibleAssetsTranslationAdjustments	-2701704
	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1.00	pure
	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period Total Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue	599010
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.43
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0064	pure
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.39
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14302439	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5760	pure
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1090015	shares
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.379	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3534789
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	126124	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13212424	shares
	us-gaap	Sales Revenue Net SalesRevenueNet	33985429
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1145493
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-16997
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	9096598
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	32495605
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	800000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-100332
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	1489824
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-843743
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	892265
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-590614
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4805244
	us-gaap	Operating Income Loss OperatingIncomeLoss	9196930
	us-gaap	Net Income Loss NetIncomeLoss	5648987
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3713817
	us-gaap	Inventory Write Down InventoryWriteDown	164300
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	14497707
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	14036
	us-gaap	Costs And Expenses CostsAndExpenses	24788499
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-252642
	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	400325
	us-gaap	Share Based Compensation ShareBasedCompensation	633073
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	135353
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2132386
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	147033
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7459519
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3447611
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-4268
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1433334
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-920168
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1679579
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-170035
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-335
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	147033
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2182129
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	400325
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1022984
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	633073
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1145493
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2831273
	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1.00	pure
	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period Total Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue	1241759
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	650000	shares
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
CY2012Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14443794	shares
CY2012Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1181771	shares
CY2012Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.386	pure
CY2012Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
CY2012Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	99245	shares
CY2012Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13262023	shares
CY2012Q2	us-gaap	Sales Revenue Net SalesRevenueNet	19624769
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6084741
CY2012Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	18882277
CY2012Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-49129
CY2012Q2	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	742492
CY2012Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1600204
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2136664
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	6133870
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	3736868
CY2012Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	8084226
CY2012Q2	us-gaap	Costs And Expenses CostsAndExpenses	13490899
CY2012Q2	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	32377
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4108503
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2347873
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5760	pure
CY2013Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1068354	shares
CY2013Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.370	pure
CY2012Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	506706
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	312563
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1298170
CY2012Q2	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1.00	pure
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.44
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0065	pure
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14578927	shares
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	469618	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	20000	shares
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13510573	shares
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	20828377
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	9362111
CY2013Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	20067407
CY2013Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-36381
CY2013Q2	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	760970
CY2013Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	340095
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6234987
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	9398492
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	5894892
CY2013Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6311332
CY2013Q2	us-gaap	Costs And Expenses CostsAndExpenses	11429885
CY2013Q2	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	131032
CY2013Q2	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	30859
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3400679
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3467219
CY2013Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	514425
CY2013Q2	us-gaap	Restructuring Charges RestructuringCharges	111178
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	365367
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1829052
CY2013Q2	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1.00	pure
CY2012Q4	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	2500000

Files In Submission

Name	View Source	Status
0001157523-13-003914-index-headers.html	Edgar Link	pending
0001157523-13-003914-index.html	Edgar Link	pending
0001157523-13-003914.txt	Edgar Link	pending
0001157523-13-003914-xbrl.zip	Edgar Link	pending
a50683805.htm	Edgar Link	pending
a50683805ex31_1.htm	Edgar Link	pending
a50683805ex31_2.htm	Edgar Link	pending
a50683805ex32_1.htm	Edgar Link	pending
anik-20130630.xml	Edgar Link	completed
anik-20130630.xsd	Edgar Link	pending
anik-20130630_cal.xml	Edgar Link	unprocessable
anik-20130630_def.xml	Edgar Link	unprocessable
anik-20130630_lab.xml	Edgar Link	unprocessable
anik-20130630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R40.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R41.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R42.xml	Edgar Link	unprocessable
R43.htm	Edgar Link	pending
R43.xml	Edgar Link	unprocessable
R44.htm	Edgar Link	pending
R44.xml	Edgar Link	unprocessable
R45.htm	Edgar Link	pending
R45.xml	Edgar Link	unprocessable
R46.htm	Edgar Link	pending
R46.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANIK
Anika Therapeutics, Inc. Stock $anik

2013 Q3 Form 10-Q Financial Statement

#000115752313003914 Filed on August 06, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIK Anika Therapeutics, Inc. Stock $anik

2013 Q3 Form 10-Q Financial Statement

#000115752313003914 Filed on August 06, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIK
Anika Therapeutics, Inc. Stock $anik